
Aktuelle Studien zum Urothel- und Harnblasenkarzinom
Sie befinden sich hier:
Laufende, nicht mehr rekrutierende Studien zum Harnblasenkarzinom
Immunomedics: A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Subjects with Metastatic or Locally Advanced Unresectable Urothelial Cancer” Protocol: IMMU-132-13 |
SGN22E-003 An open-label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab, versus chemotherapy alone in previously untreated locally advanced or metastatic urothelial cancer |
MK-3475-866 / KEYNOTE 866 Peri-operative Pembrolizumab + Neoadjuvant Chemotherapv vs Periop. Placebo + Neoadjuvant Chemotherapy in Cisplatin Eligible Patients with Muscle-Invasive Bladder Cancer |
POTOMAC Phase III Randomized, Open-label, Multi-center, Global Study of Durvalumab and Bacillus Calmette-Guerin (BCG) administered as Combination Therapy versus BCG alone in High Risk, BCG-Naïve Non-muscle-Invasive Bladder Cancer Patients |